jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
International Journal of Pharmaceutical InvestigationNOW IN
Article

Efficacy and Safety of Inhaled Indacaterol and Tiotropium in Patients of Chronic Obstructive Pulmonary Disease

Mohammad Sajid Alam1, Jameel Ahmad1★, Anil Kumar1, Mohammad Shameem1★ Corresponding author

  1. 1Pharmacology and Department of Tuberculosis and Respiratory diseases of J.N. Medical College and Hospital, A.M.U., Aligarh, Uttar Pradesh, INDIA.

CORRESPONDENCE

Jameel Ahmad

Pharmacology and Department of Tuberculosis and Respiratory diseases of J.N. Medical College and Hospital, A.M.U., Aligarh, Uttar Pradesh, INDIA.

ahmad.drjameel@gmail.com

Received: 05-01-2020; Revised: 07-02-2020; Accepted: 29-02-2020.

Volume 10, Issue 2 · pp. 217–220 · PUBLISHED · DOI: 10.5530/ijpi.2020.2.40

View on IJPI original site ↗

ABSTRACT

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide. Indacaterol is a new once daily inhaled bronchodilator, recently approved for the treatment of COPD. Once daily dosing is an important step to improve the adherence and compliance of the patients. Methods: Efficacy and Safety of Indacaterol and Tiotropium in Patients of COPD with Stage-2 and Stage-3 GOLD criteria were compared. Total 119 patients were divided into Indacaterol group and Tiotropium group receiving 150 mcg daily of Indacaterol and 18 mcg daily of Tiotropium in each group respectively. Efficacy treatment was determined by assessment of Pulmonary function test (PFT), Symptom score and SGRQ (St. George’s Respiratory Questionnaires) score at day zero (before therapeutic intervention) and at two weeks of interval till 24 weeks. Results: The treatment with inhaled indacaterol 150 mcg once daily and inhaled tiotropium 18 mcg once daily improved spirometric variable, FEV1, decrease in mean Symptoms score and in mean SGRQ in Grade-2 and Grade-3 COPD patients. Conclusion: Indacaterol (150 mcg/day) is non-inferior to tiotropium (18 mcg /day) in efficacy and safety profile of Grade-2 and Grade-3 patients with COPD.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Alam, M. S., Ahmad, J., Kumar, A., & Shameem, M. (). Efficacy and Safety of Inhaled Indacaterol and Tiotropium in Patients of Chronic Obstructive Pulmonary Disease. International Journal of Pharmaceutical Investigation, 10(2), 217–220. https://doi.org/10.5530/ijpi.2020.2.40